MEDICLIN AG (MED.DE) Fundamental Analysis & Valuation

FRA:MED • DE0006595101

Current stock price

3.44 EUR
0 (0%)
Last:

This MED.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. MED.DE Profitability Analysis

1.1 Basic Checks

  • In the past year MED was profitable.
  • In the past year MED had a positive cash flow from operations.
  • MED had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years MED had a positive operating cash flow.
MED.DE Yearly Net Income VS EBIT VS OCF VS FCFMED.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

1.2 Ratios

  • MED has a Return On Assets of 3.03%. This is comparable to the rest of the industry: MED outperforms 60.00% of its industry peers.
  • MED has a Return On Equity of 10.24%. This is comparable to the rest of the industry: MED outperforms 60.00% of its industry peers.
  • The Return On Invested Capital of MED (6.23%) is better than 70.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MED is in line with the industry average of 6.23%.
  • The last Return On Invested Capital (6.23%) for MED is above the 3 year average (5.02%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.03%
ROE 10.24%
ROIC 6.23%
ROA(3y)1.52%
ROA(5y)1.15%
ROE(3y)5.3%
ROE(5y)4.24%
ROIC(3y)5.02%
ROIC(5y)3.67%
MED.DE Yearly ROA, ROE, ROICMED.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10

1.3 Margins

  • MED's Profit Margin of 3.17% is fine compared to the rest of the industry. MED outperforms 66.67% of its industry peers.
  • MED's Profit Margin has improved in the last couple of years.
  • MED has a Operating Margin of 6.88%. This is comparable to the rest of the industry: MED outperforms 60.00% of its industry peers.
  • In the last couple of years the Operating Margin of MED has grown nicely.
  • The Gross Margin of MED (84.41%) is better than 76.67% of its industry peers.
  • In the last couple of years the Gross Margin of MED has remained more or less at the same level.
Industry RankSector Rank
OM 6.88%
PM (TTM) 3.17%
GM 84.41%
OM growth 3Y41.41%
OM growth 5Y220.89%
PM growth 3Y34.34%
PM growth 5YN/A
GM growth 3Y1.13%
GM growth 5Y0.29%
MED.DE Yearly Profit, Operating, Gross MarginsMED.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MED.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MED is creating some value.
  • The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
  • MED has about the same amout of shares outstanding than it did 5 years ago.
  • MED has a better debt/assets ratio than last year.
MED.DE Yearly Shares OutstandingMED.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
MED.DE Yearly Total Debt VS Total AssetsMED.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.62, we must say that MED is in the distress zone and has some risk of bankruptcy.
  • MED has a Altman-Z score (1.62) which is comparable to the rest of the industry.
  • MED has a debt to FCF ratio of 7.66. This is a slightly negative value and a sign of low solvency as MED would need 7.66 years to pay back of all of its debts.
  • MED has a Debt to FCF ratio of 7.66. This is in the better half of the industry: MED outperforms 63.33% of its industry peers.
  • A Debt/Equity ratio of 1.46 is on the high side and indicates that MED has dependencies on debt financing.
  • With a Debt to Equity ratio value of 1.46, MED perfoms like the industry average, outperforming 46.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF 7.66
Altman-Z 1.62
ROIC/WACC1.22
WACC5.12%
MED.DE Yearly LT Debt VS Equity VS FCFMED.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • MED has a Current Ratio of 1.68. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Current ratio value of 1.68, MED is doing good in the industry, outperforming 80.00% of the companies in the same industry.
  • MED has a Quick Ratio of 1.65. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
  • MED has a Quick ratio of 1.65. This is amongst the best in the industry. MED outperforms 93.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.68
Quick Ratio 1.65
MED.DE Yearly Current Assets VS Current LiabilitesMED.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MED.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 2.64% over the past year.
  • MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 39.23% yearly.
  • The Revenue has been growing slightly by 5.13% in the past year.
  • The Revenue has been growing slightly by 3.69% on average over the past years.
EPS 1Y (TTM)2.64%
EPS 3Y39.23%
EPS 5YN/A
EPS Q2Q%-96.23%
Revenue 1Y (TTM)5.13%
Revenue growth 3Y3.65%
Revenue growth 5Y3.69%
Sales Q2Q%3.65%

3.2 Future

  • Based on estimates for the next years, MED will show a small growth in Earnings Per Share. The EPS will grow by 1.36% on average per year.
  • MED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.28% yearly.
EPS Next Y1.37%
EPS Next 2Y1.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.8%
Revenue Next 2Y3.65%
Revenue Next 3Y3.28%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MED.DE Yearly Revenue VS EstimatesMED.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
MED.DE Yearly EPS VS EstimatesMED.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

8

4. MED.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 6.37, the valuation of MED can be described as very cheap.
  • MED's Price/Earnings ratio is rather cheap when compared to the industry. MED is cheaper than 100.00% of the companies in the same industry.
  • MED's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.89.
  • The Price/Forward Earnings ratio is 4.60, which indicates a rather cheap valuation of MED.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MED indicates a rather cheap valuation: MED is cheaper than 100.00% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 38.50. MED is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 6.37
Fwd PE 4.6
MED.DE Price Earnings VS Forward Price EarningsMED.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • MED's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MED is cheaper than 96.67% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MED is valued cheaper than 90.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.2
EV/EBITDA 2.87
MED.DE Per share dataMED.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of MED may justify a higher PE ratio.
PEG (NY)4.65
PEG (5Y)N/A
EPS Next 2Y1.36%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. MED.DE Dividend Analysis

5.1 Amount

  • MED has a Yearly Dividend Yield of 1.16%.
  • Compared to an average industry Dividend Yield of 1.84, MED has a dividend in line with its industry peers.
  • MED's Dividend Yield is slightly below the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.16%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MED.DE Yearly Dividends per shareMED.DE Yearly Dividends per shareYearly Dividends per share 2019 2025 2026 0.01 0.02 0.03 0.04

5.3 Sustainability

  • MED pays out 7.45% of its income as dividend. This is a sustainable payout ratio.
DP7.45%
EPS Next 2Y1.36%
EPS Next 3YN/A
MED.DE Yearly Income VS Free CF VS DividendMED.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M
MED.DE Dividend Payout.MED.DE Dividend Payout, showing the Payout Ratio.MED.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MED.DE Fundamentals: All Metrics, Ratios and Statistics

MEDICLIN AG

FRA:MED (4/17/2026, 7:00:00 PM)

3.44

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-26
Earnings (Next)05-04
Inst Owners0.76%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap163.40M
Revenue(TTM)804.32M
Net Income(TTM)25.49M
Analysts80
Price Target6.32 (83.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.16%
Yearly Dividend0.04
Dividend Growth(5Y)N/A
DP7.45%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.83%
PT rev (3m)7.83%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)9.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.29%
Revenue NY rev (3m)2.75%
Valuation
Industry RankSector Rank
PE 6.37
Fwd PE 4.6
P/S 0.2
P/FCF 3.2
P/OCF 1.6
P/B 0.66
P/tB 0.7
EV/EBITDA 2.87
EPS(TTM)0.54
EY15.7%
EPS(NY)0.75
Fwd EY21.73%
FCF(TTM)1.07
FCFY31.22%
OCF(TTM)2.16
OCFY62.69%
SpS16.93
BVpS5.24
TBVpS4.88
PEG (NY)4.65
PEG (5Y)N/A
Graham Number7.97983 (131.97%)
Profitability
Industry RankSector Rank
ROA 3.03%
ROE 10.24%
ROCE 8.24%
ROIC 6.23%
ROICexc 7.98%
ROICexgc 8.25%
OM 6.88%
PM (TTM) 3.17%
GM 84.41%
FCFM 6.34%
ROA(3y)1.52%
ROA(5y)1.15%
ROE(3y)5.3%
ROE(5y)4.24%
ROIC(3y)5.02%
ROIC(5y)3.67%
ROICexc(3y)6.5%
ROICexc(5y)4.72%
ROICexgc(3y)6.76%
ROICexgc(5y)4.97%
ROCE(3y)6.64%
ROCE(5y)4.85%
ROICexgc growth 3Y50.89%
ROICexgc growth 5Y238.46%
ROICexc growth 3Y54.07%
ROICexc growth 5Y243.02%
OM growth 3Y41.41%
OM growth 5Y220.89%
PM growth 3Y34.34%
PM growth 5YN/A
GM growth 3Y1.13%
GM growth 5Y0.29%
F-Score7
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF 7.66
Debt/EBITDA 3.13
Cap/Depr 85.39%
Cap/Sales 6.39%
Interest Coverage 2.64
Cash Conversion 88.63%
Profit Quality 200.16%
Current Ratio 1.68
Quick Ratio 1.65
Altman-Z 1.62
F-Score7
WACC5.12%
ROIC/WACC1.22
Cap/Depr(3y)72.65%
Cap/Depr(5y)55.5%
Cap/Sales(3y)5.71%
Cap/Sales(5y)4.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.64%
EPS 3Y39.23%
EPS 5YN/A
EPS Q2Q%-96.23%
EPS Next Y1.37%
EPS Next 2Y1.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.13%
Revenue growth 3Y3.65%
Revenue growth 5Y3.69%
Sales Q2Q%3.65%
Revenue Next Year4.8%
Revenue Next 2Y3.65%
Revenue Next 3Y3.28%
Revenue Next 5YN/A
EBIT growth 1Y3.51%
EBIT growth 3Y46.57%
EBIT growth 5Y232.74%
EBIT Next Year84.02%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.2%
FCF growth 3Y80.88%
FCF growth 5Y-11.22%
OCF growth 1Y27.15%
OCF growth 3Y43.54%
OCF growth 5Y-2.84%

MEDICLIN AG / MED.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to MED.DE.


Can you provide the valuation status for MEDICLIN AG?

ChartMill assigns a valuation rating of 8 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.


How profitable is MEDICLIN AG (MED.DE) stock?

MEDICLIN AG (MED.DE) has a profitability rating of 6 / 10.


What is the earnings growth outlook for MEDICLIN AG?

The Earnings per Share (EPS) of MEDICLIN AG (MED.DE) is expected to grow by 1.37% in the next year.


Is the dividend of MEDICLIN AG sustainable?

The dividend rating of MEDICLIN AG (MED.DE) is 3 / 10 and the dividend payout ratio is 7.45%.